Elliott Dasenbrook
Pulmonary Disease · Cleveland, OHNPI 1780772632
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (44.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Gilead at 48.1% of the total. Reporting peaked in 2019 at $56,261 and has fallen 86.9% since, to $7,370 in 2022. Among pulmonary disease clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 118 payments — averaging $963.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$55K
- Insmed, Inc.$23K
- Vertex$10K
- Mylan Specialty L.p.$8K
- Advanced Respiratory, Inc$7K
- Lupin Inc.$7K
- plus $5K from 6 others
Across 347 payments — averaging $986.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Insmed, Inc.$292K
- Vertex$30K
- AbbVie$20K
- Chiesi USA, Inc.$425
What the payments were for
- Consulting fees$47,27542%
- Speaking & faculty fees$50,80445%
- Travel & lodging$13,00011%
- Food & beverage$2,4542%
- Education$990%
- Gifts$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 51 | $54,674 |
| Insmed, Inc. | 21 | $23,182 |
| Vertex | 21 | $9,693 |
| Mylan Specialty L.p. | 10 | $7,537 |
| Advanced Respiratory, Inc | 7 | $6,854 |
| Lupin Inc. | 2 | $6,588 |
| Electromed, Inc. | 1 | $2,379 |
| Shionogi Inc | 1 | $950 |
| Cipla USA Inc. | 1 | $850 |
| Hill-rom Company, Inc | 1 | $800 |
| Chiesi USA, Inc. | 1 | $128 |
| Genentech USA, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Cayston$9,610
- The Vest System 205 Acute Care$7,545
- The Vest System Model 105 Home Care$7,545
- TOBI$7,160
- The Monarch Airway Clearance System$6,745
- Arikayce$3,475
- TRIKAFTA$2,448
- SMARTVEST$2,379
- Fetroja$950
- SYMDEKO$890
- 4$850
- KALYDECO$668
- ORKAMBI$668
- BETHKIS$128
- PERTZYE$128
- TOBI Podhaler$111
How this compares
$113,650 in reported general payments places this provider in the 95th percentile of 571 pulmonary disease providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Azithromycin | 11 | $276 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Cleveland
- Kristin HighlandCleveland$551K
- Joseph CiceniaCleveland$350K
- Michael MachuzakCleveland$286K
- Marie BudevCleveland$159K
- Leslie TolleCleveland$136K
- James StollerCleveland$101K
- Gustavo Heresi DavilaCleveland$98K
- Bryan BennCleveland$96K
- Thomas GildeaCleveland$69K
- Daniel CulverCleveland$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.